Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ABSTRAL vs ALLEGRA ALLERGY
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.
Fexofenadine is a selective peripheral H1-receptor antagonist. It inhibits histamine-induced vasodilation and bronchoconstriction by blocking the H1 receptor, thereby reducing allergic symptoms.
Management of breakthrough pain in cancer patients aged 18 and older who are already receiving and tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain.
Relief of symptoms associated with seasonal allergic rhinitis (sneezing, rhinorrhea, itchy nose/palate/throat, itchy/watery/red eyes),Treatment of uncomplicated skin manifestations of chronic idiopathic urticaria (pruritus and hives)
For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.
Fexofenadine 180 mg orally once daily.
Terminal elimination half-life: 6-10 hours (mean 8 hours); prolonged in elderly and hepatic impairment
Terminal elimination half-life is 14.4 hours (range 8–16 hours) in healthy adults. In renal impairment, half-life may be prolonged; dose adjustment recommended for Cr Cl <30 m L/min.
Hepatic metabolism primarily via CYP3A4; major metabolites include norfentanyl (inactive) and other minor metabolites.
Fexofenadine undergoes minimal hepatic metabolism; approximately 5% of the dose is metabolized by CYP3A4. It is primarily excreted unchanged in feces and urine.
Renal: ~70% as metabolites (primarily fentanyl conjugates and norfentanyl), ~10% unchanged; Fecal: ~9%; Biliary: minimal
Primarily eliminated in feces (80%) and urine (approximately 15%) as unchanged drug. Biliary secretion contributes significantly.
80-85% bound primarily to albumin and alpha-1-acid glycoprotein
60-70% bound to plasma proteins (mainly albumin and α1-acid glycoprotein).
4-6 L/kg; large Vd indicates extensive tissue distribution
Steady-state volume of distribution (Vdss) is 5.4–16 L/kg (mean ~12 L/kg). The large Vd indicates extensive tissue distribution.
Sublingual: 70-90% (mean 80%); buccal: 50-65%; oral: ~30% due to first-pass metabolism
Oral bioavailability is approximately 30% (range 25–40%) due to first-pass metabolism. Bioavailability is reduced by fruit juices (e.g., grapefruit, apple, orange).
No specific GFR-based dose adjustment recommended; use caution in severe renal impairment (Cr Cl <30 m L/min) due to potential accumulation of fentanyl.
GFR 40-59 m L/min: 60 mg once daily; GFR 15-39 m L/min: 60 mg every other day; GFR <15 m L/min: not recommended.
For Child-Pugh Class A or B: no adjustment required; for Child-Pugh Class C: reduce dose and monitor closely for toxicity due to reduced clearance.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Insufficient data for severe (Child-Pugh C).
Not approved for pediatric patients <18 years; safety and efficacy not established.
Children 2-11 years: 30 mg orally twice daily; Children 12 years and older: same as adult dosing.
Initiate at the lowest available dose (100 mcg) and titrate cautiously; elderly patients may have altered pharmacokinetics and increased sensitivity to fentanyl.
No specific dose adjustment, but elderly patients may be more sensitive to anticholinergic effects; consider starting at lower end of dosing range. No renal adjustment needed if renal function normal.
Risk of respiratory depression, addiction, abuse, and misuse; risk of accidental ingestion; risk of medication errors resulting in fatal overdose; life-threatening respiratory depression in opioid-non-tolerant patients; risk of opioid analgesic drug interactions with CNS depressants; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy.
None.
Respiratory depression, QT prolongation, serotonin syndrome, adrenal insufficiency, severe hypotension, seizures, biliary tract disease, gastrointestinal obstruction, withdrawal syndrome, and risk of overdose with alcohol or other CNS depressants.
Use with caution in patients with renal impairment (Cr Cl < 80 m L/min) as exposure is increased; consider dose adjustment.,Avoid concurrent use with aluminum- and magnesium-containing antacids, which reduce fexofenadine absorption by up to 40%.,Potential for QT prolongation at high doses (rare); caution in patients with pre-existing QT prolongation or electrolyte imbalances.,Not recommended for severe hepatic impairment due to lack of data.
Hypersensitivity to fentanyl or any components; opioid-non-tolerant patients; acute or severe bronchial asthma; known or suspected gastrointestinal obstruction; concurrent use of MAOIs or within 14 days of discontinuation.
Hypersensitivity to fexofenadine or any component of the formulation,End-stage renal disease (ESRD) with Cr Cl < 15 m L/min (use not recommended)
Avoid grapefruit and grapefruit juice during treatment as they inhibit CYP3A4, increasing fentanyl exposure. No other significant food interactions; however, avoid alcohol due to additive CNS depressant effects. Maintain consistent meal timing relative to dosing to minimize variability.
Fruit juices (apple, orange, grapefruit) significantly decrease absorption of fexofenadine; avoid concurrent consumption. No other significant food interactions.
FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in animal studies. Second trimester: No specific malformation risk. Third trimester: Prolonged use can cause neonatal opioid withdrawal syndrome (NOWS) and respiratory depression at birth.
Fexofenadine (ALLEGRA ALLERGY) is classified as FDA Pregnancy Category C. Animal studies have shown no teratogenicity at doses up to 2-3 times the human dose. There are no adequate, well-controlled studies in pregnant women. First trimester: Limited data suggest no increased risk of major malformations. Second and third trimesters: No known specific fetal risks from antihistamine use; however, use only if clearly needed due to lack of extensive human data.
Minimal excretion into breast milk; M/P ratio not reported. Fentanyl is poorly absorbed orally, making significant infant exposure unlikely. Monitor infant for sedation, respiratory depression, and poor feeding. Avoid use in breastfeeding mothers with opioid dependence or high doses.
Fexofenadine is excreted into human breast milk in small amounts. The milk-to-plasma (M/P) ratio is approximately 0.24. Based on limited data, the relative infant dose is estimated to be less than 5% of the maternal weight-adjusted dose, which is considered low. However, caution is advised due to potential effects on the infant, such as drowsiness or irritability. Use only if clearly needed, and monitor the infant for adverse effects.
Pregnancy increases clearance and volume of distribution, potentially reducing drug levels. Dose adjustments may be needed: initiate with lower doses and titrate to effect; consider increasing frequency or using breakthrough doses. Monitor for inadequate analgesia. Avoid abrupt discontinuation; taper if stopping.
No specific dosing adjustments are recommended for fexofenadine during pregnancy, as pharmacokinetic data are limited. However, due to physiological changes in pregnancy (e.g., increased plasma volume, renal clearance), the standard adult dose (60 mg twice daily or 180 mg once daily) may require cautious use; consider lowest effective dose. No formal studies have been conducted to determine dose modifications.
ABSTRAL (fentanyl sublingual spray) is a transmucosal immediate-release fentanyl (TIRF) formulation indicated for breakthrough pain in opioid-tolerant patients. Due to high bioavailability (~70%) and rapid onset (peak plasma concentration at 15-30 minutes), initial titration must start with 100 mcg, with dose escalation based on efficacy and tolerability. Weight-based conversion from other fentanyl products is not valid; utilize the provided conversion table. Patients must have a rescue agent (e.g., naloxone) available. Concomitant use with CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) or inducers (e.g., rifampin, carbamazepine) requires dose adjustment. Avoid use in opioid-naïve patients due to risk of respiratory depression.
Fexofenadine is a second-generation antihistamine with minimal CNS penetration, causing less sedation than first-generation agents. Onset of action is within 1 hour; peak effect at 2-3 hours. Avoid in patients with severe renal impairment (Cr Cl <30 m L/min) due to reduced clearance. Antacids containing aluminum or magnesium reduce absorption; separate by at least 2 hours. No significant QT prolongation at therapeutic doses.
Use only for breakthrough cancer pain while on around-the-clock opioid therapy.,Do not switch from other fentanyl products based on dose; follow specific conversion instructions.,Spray entire dose into mouth; do not swallow or rinse for at least 10 minutes.,Store at room temperature, away from children and pets.,Dispose of unused units via drug take-back program or by flushing down toilet per FDA guidelines.,Never share this medication with others; death may occur.,Seek emergency if severe drowsiness, confusion, or slow breathing occurs.
Take with water; do not take with fruit juices (apple, orange, grapefruit) as they reduce absorption.,Do not use with antacids containing aluminum or magnesium; wait at least 2 hours between doses.,May cause mild drowsiness in some patients; avoid driving if affected.,Do not exceed recommended dose; overdose may cause dizziness, drowsiness, or dry mouth.,Store at room temperature away from moisture and heat.,Consult healthcare provider if symptoms persist >7 days or if fever occurs.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ABSTRAL vs ALLEGRA ALLERGY, answered by our medical review team.
ABSTRAL is a Opioid Analgesic that works by Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.. ALLEGRA ALLERGY is a Antihistamine (Nonsedating) that works by Fexofenadine is a selective peripheral H1-receptor antagonist. It inhibits histamine-induced vasodilation and bronchoconstriction by blocking the H1 receptor, thereby reducing allergic symptoms.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ABSTRAL and ALLEGRA ALLERGY depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ABSTRAL is: For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.. The standard adult dose of ALLEGRA ALLERGY is: Fexofenadine 180 mg orally once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ABSTRAL and ALLEGRA ALLERGY in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ABSTRAL is classified as Category C. FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in a. ALLEGRA ALLERGY is classified as Category C. Fexofenadine (ALLEGRA ALLERGY) is classified as FDA Pregnancy Category C. Animal studies have shown no teratogenicity at doses up to 2-3 times the human dose. There are no adequate. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.